| Autor: |
Cadar R; Department of Surgery, Gr. T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.; General Surgery and Liver Transplant Clinic, St. Spiridon University Hospital, 700111 Iasi, Romania., Lupascu Ursulescu C; Department of Radiology, Gr. T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.; Radiology Clinic, St. Spiridon University Hospital, 700111 Iasi, Romania., Vasilescu AM; Department of Surgery, Gr. T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.; General Surgery and Liver Transplant Clinic, St. Spiridon University Hospital, 700111 Iasi, Romania., Trofin AM; Department of Surgery, Gr. T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.; General Surgery and Liver Transplant Clinic, St. Spiridon University Hospital, 700111 Iasi, Romania., Zabara M; Department of Surgery, Gr. T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.; General Surgery and Liver Transplant Clinic, St. Spiridon University Hospital, 700111 Iasi, Romania., Rusu-Andriesi D; Department of Surgery, Gr. T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.; General Surgery and Liver Transplant Clinic, St. Spiridon University Hospital, 700111 Iasi, Romania., Ciuntu B; Department of Surgery, Gr. T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.; General Surgery and Liver Transplant Clinic, St. Spiridon University Hospital, 700111 Iasi, Romania., Muzica C; Department of Gastroenterology, Gr. T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.; Institute of Gastroenterology and Hepatology, St. Spiridon University Hospital, 700111 Iasi, Romania., Lupascu CD; Department of Surgery, Gr. T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.; General Surgery and Liver Transplant Clinic, St. Spiridon University Hospital, 700111 Iasi, Romania. |
| Abstrakt: |
Non-alcoholic fatty liver disease (NAFLD) has gained attention in the last few years due to its increasing prevalence worldwide becoming a global epidemic. The increasing incidence of NAFLD and the concurrent increase in the number of hepatocellular carcinoma (HCC) cases at a global level is a matter of concern. HCC has several risk factors, of which NAFLD and its associated metabolic disturbances-type 2 diabetes mellitus, obesity, and dyslipidemia-are of great interest due to their accelerating rise in incidence worldwide. There is a high amount of data derived from basic and clinical studies that reveal the molecular pathways that drive NAFLD-associated HCC. Based on these findings, new prevention, surveillance, and treatment strategies are emerging. However, current data on treatment modalities in NAFLD-associated HCC are still scarce, though the results from non-NAFLD HCC studies are promising and could provide a basis for a future research agenda to address NAFLD/NASH patients. Clinicians should carefully assess all the clinical and radiological parameters and establish a prognosis based on the Barcelona Clinic Liver Cancer classification and discuss in a multidisciplinary team the treatment strategy. The specific factors associated with NAFLD-associated HCC which can have a negative impact on survival even in patients with early HCC, such as cardiovascular disease, type 2 diabetes, and obesity, should be taken into consideration. This review aims to discuss the latest recommendations regarding the diagnosis and treatment of NAFLD-associated HCC and the remaining challenges. |
